BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $355,000 | +3.5% | 4,123 | -2.3% | 0.17% | +6.4% |
| Q1 2020 | $343,000 | -31.1% | 4,219 | -29.1% | 0.16% | +13.0% |
| Q4 2019 | $498,000 | -53.4% | 5,953 | -51.3% | 0.14% | -30.3% |
| Q3 2019 | $1,069,000 | +99.8% | 12,218 | +87.2% | 0.20% | +108.4% |
| Q2 2019 | $535,000 | -0.2% | 6,527 | -0.9% | 0.10% | +2.2% |
| Q1 2019 | $536,000 | +22.4% | 6,587 | -1.0% | 0.09% | +3.3% |
| Q4 2018 | $438,000 | -22.1% | 6,656 | -8.7% | 0.09% | -26.2% |
| Q3 2018 | $562,000 | -65.0% | 7,293 | -66.5% | 0.12% | -66.5% |
| Q2 2018 | $1,605,000 | +316.9% | 21,741 | +266.8% | 0.36% | +283.2% |
| Q1 2018 | $385,000 | -82.3% | 5,927 | -82.4% | 0.10% | -82.4% |
| Q4 2017 | $2,180,000 | -44.8% | 33,726 | -46.4% | 0.54% | -28.7% |
| Q3 2017 | $3,951,000 | -52.7% | 62,964 | -54.4% | 0.76% | -46.3% |
| Q2 2017 | $8,357,000 | +23.2% | 138,044 | +5.5% | 1.41% | -2.9% |
| Q1 2017 | $6,783,000 | +12.2% | 130,787 | -4.0% | 1.45% | +1.1% |
| Q4 2016 | $6,043,000 | – | 136,298 | – | 1.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |